Nurix Therapeutics IncNASDAQ:NRIX
- LAST PRICE11.5400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots11.0000/ 1
- Ask / Lots11.5600/ 2
- Open / Previous Close12.2900 / 11.5400
- Day Range
- 52 Week Range
- Volume229,756
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRIX |
|---|---|---|
| 09:32 ET | 2381 | 12.29 |
| 09:33 ET | 100 | 12.26 |
| 09:39 ET | 100 | 12.2537 |
| 09:42 ET | 100 | 12.12 |
| 09:44 ET | 200 | 12.09 |
| 09:46 ET | 100 | 11.97 |
| 10:00 ET | 400 | 12.01 |
| 10:06 ET | 250 | 12.04 |
| 10:15 ET | 200 | 11.92 |
| 10:18 ET | 2400 | 12.02 |
| 10:27 ET | 200 | 11.98 |
| 10:29 ET | 200 | 11.93 |
| 10:40 ET | 100 | 11.82 |
| 10:44 ET | 100 | 11.81 |
| 10:47 ET | 100 | 11.79 |
| 10:51 ET | 2900 | 11.835 |
| 10:54 ET | 300 | 11.81 |
| 10:56 ET | 100 | 11.77 |
| 10:58 ET | 300 | 11.73 |
| 11:02 ET | 1100 | 11.72 |
| 11:03 ET | 100 | 11.7 |
| 11:05 ET | 592 | 11.7 |
| 11:09 ET | 1600 | 11.68 |
| 11:12 ET | 100 | 11.68 |
| 11:14 ET | 100 | 11.66 |
| 11:16 ET | 100 | 11.62 |
| 11:18 ET | 400 | 11.655 |
| 11:20 ET | 638 | 11.71 |
| 11:21 ET | 300 | 11.66 |
| 11:23 ET | 800 | 11.66 |
| 11:25 ET | 700 | 11.59 |
| 11:30 ET | 400 | 11.6 |
| 11:32 ET | 100 | 11.66 |
| 11:36 ET | 900 | 11.6 |
| 11:41 ET | 100 | 11.59 |
| 11:43 ET | 600 | 11.6 |
| 11:50 ET | 3482 | 11.6 |
| 11:57 ET | 100 | 11.63 |
| 11:59 ET | 200 | 11.63 |
| 12:01 ET | 19285 | 11.775 |
| 12:03 ET | 700 | 11.72 |
| 12:06 ET | 346 | 11.68 |
| 12:10 ET | 100 | 11.65 |
| 12:12 ET | 412 | 11.6892 |
| 12:14 ET | 100 | 11.66 |
| 12:17 ET | 100 | 11.62 |
| 12:21 ET | 560 | 11.635 |
| 12:24 ET | 100 | 11.68 |
| 12:26 ET | 100 | 11.67 |
| 12:32 ET | 600 | 11.76 |
| 12:33 ET | 100 | 11.77 |
| 12:35 ET | 700 | 11.71 |
| 12:46 ET | 894 | 11.57 |
| 12:48 ET | 100 | 11.57 |
| 12:51 ET | 527 | 11.65 |
| 12:53 ET | 252 | 11.63 |
| 12:55 ET | 793 | 11.67 |
| 12:57 ET | 200 | 11.71 |
| 01:04 ET | 233 | 11.75 |
| 01:09 ET | 200 | 11.77 |
| 01:11 ET | 200 | 11.78 |
| 01:13 ET | 911 | 11.74 |
| 01:18 ET | 300 | 11.71 |
| 01:20 ET | 400 | 11.75 |
| 01:22 ET | 1600 | 11.79 |
| 01:24 ET | 100 | 11.79 |
| 01:27 ET | 800 | 11.73 |
| 01:29 ET | 300 | 11.785 |
| 01:31 ET | 400 | 11.755 |
| 01:33 ET | 100 | 11.73 |
| 01:36 ET | 500 | 11.7 |
| 01:40 ET | 1000 | 11.66 |
| 01:47 ET | 200 | 11.67 |
| 01:49 ET | 300 | 11.67 |
| 01:51 ET | 100 | 11.67 |
| 01:54 ET | 1054 | 11.64 |
| 02:00 ET | 851 | 11.63 |
| 02:02 ET | 400 | 11.64 |
| 02:03 ET | 600 | 11.67 |
| 02:05 ET | 500 | 11.7 |
| 02:09 ET | 200 | 11.75 |
| 02:12 ET | 607 | 11.75 |
| 02:14 ET | 1318 | 11.79 |
| 02:20 ET | 800 | 11.88 |
| 02:21 ET | 600 | 11.83 |
| 02:25 ET | 100 | 11.83 |
| 02:27 ET | 2600 | 11.805 |
| 02:30 ET | 600 | 11.79 |
| 02:34 ET | 100 | 11.775 |
| 02:36 ET | 1200 | 11.74 |
| 02:38 ET | 600 | 11.76 |
| 02:41 ET | 200 | 11.77 |
| 02:43 ET | 3100 | 11.7 |
| 02:48 ET | 100 | 11.725 |
| 02:50 ET | 200 | 11.725 |
| 02:52 ET | 1259 | 11.66 |
| 02:57 ET | 1575 | 11.72 |
| 02:59 ET | 300 | 11.76 |
| 03:01 ET | 600 | 11.7 |
| 03:03 ET | 2692 | 11.675 |
| 03:06 ET | 1600 | 11.67 |
| 03:08 ET | 100 | 11.68 |
| 03:10 ET | 839 | 11.65 |
| 03:12 ET | 513 | 11.665 |
| 03:14 ET | 1450 | 11.61 |
| 03:15 ET | 300 | 11.64 |
| 03:17 ET | 400 | 11.64 |
| 03:19 ET | 1500 | 11.63 |
| 03:21 ET | 400 | 11.66 |
| 03:24 ET | 400 | 11.67 |
| 03:26 ET | 400 | 11.68 |
| 03:28 ET | 500 | 11.655 |
| 03:30 ET | 600 | 11.67 |
| 03:32 ET | 100 | 11.69 |
| 03:33 ET | 400 | 11.65 |
| 03:35 ET | 1147 | 11.615 |
| 03:37 ET | 500 | 11.62 |
| 03:39 ET | 200 | 11.62 |
| 03:42 ET | 1100 | 11.65 |
| 03:44 ET | 700 | 11.7 |
| 03:46 ET | 1480 | 11.67 |
| 03:48 ET | 1715 | 11.625 |
| 03:50 ET | 1372 | 11.63 |
| 03:51 ET | 700 | 11.66 |
| 03:53 ET | 1325 | 11.595 |
| 03:55 ET | 3150 | 11.55 |
| 03:57 ET | 3945 | 11.55 |
| 04:00 ET | 65425 | 11.54 |
Yesterday
Nurix Therapeutics to Participate in Upcoming Investor Conferences, from 9 hours ago by GlobeNewswire
9 hours ago by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nurix Therapeutics Inc | 544.1M | -3.1x | --- |
Tango Therapeutics Inc | 541.4M | -5.3x | --- |
Zymeworks Inc | 567.7M | -2.5x | --- |
Arcturus Therapeutics Holdings Inc | 519.0M | -3.5x | --- |
Atara Biotherapeutics Inc | 478.2M | -2.0x | --- |
Repare Therapeutics Inc | 522.4M | -16.9x | --- |
Company Information
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. It leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.
Contact Information
- Headquarters
- 1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006
- Phone
- 415-660-5320
- Fax
- 415-525-4200
Executives
- Independent Chairman of the Board
- David Lacey
- President, Chief Executive Officer, Director
- Arthur Sands
- Chief Financial Officer
- Hans Van Houte
- Chief Operating Officer, Executive Vice President - Product Development
- Stefani Wolff
- Chief People Officer
- Eric Schlezinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $544.1M |
|---|---|
Revenue (TTM) | $39.2M |
Shares Outstanding | 47.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.71 |
Book Value | $7.66 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | 13.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -441.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
